Kim Branson, senior vice president and Global Head of Artificial Intelligence and Machine Learning at GSK, examines how GSK’s AI team uses ethics-driven frameworks and checklists to consider the potential implications of new AI-driven medical innovations.

Video clips from: Principled Engineering: AI and Drug Development [Entire Talk]

3 minutes

Where is AI-Driven Bioengineering Headed Next?

Watch now

9 minutes

Innovation-Driven Engagement with Regulators

Watch now

3 minutes

Ethical Science is Better Science

Watch now

3 minutes

Ethical Guardrails for AI in Drug Development

Watch now

Share Post